Form 8-K · Current Report · Filed 2024-11-06
Ionis Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Pipeline Updates
Ionis Pharmaceuticals, Inc. reported its third quarter 2024 financial results, with total revenue of $134 million. The company highlighted significant progress across its pipeline, including the U.S. launch of WAINUA for ATTRv-PN, positive CHMP opinion in Europe, and regulatory submissions for olezarsen and donidalorsen. Ionis also provided updates on several clinical trials and upcoming PDUFA dates for its pipeline programs. The company's cash position increased to $2.5 billion as of September 30, 2024.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-24-045370
- CIK
- 0000874015
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$38.80
Next session
-0.9%
Since filing
+33.4%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Exhibits (1)
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.